Comparison of exosomal microRNAs secreted by 786‑O clear cell renal carcinoma cells and HK‑2 proximal tubule‑derived cells in culture identifies microRNA‑205 as a potential biomarker of clear cell renal carcinoma

Crentsil,Victor  C.; Liu,Hui; Sellitti,Donald  F.

doi:10.3892/ol.2018.8751

Comparison of exosomal microRNAs secreted by 786‑O clear cell renal carcinoma cells and HK‑2 proximal tubule‑derived cells in culture identifies microRNA‑205 as a potential biomarker of clear cell renal carcinoma

Authors:
- Victor C. Crentsil
- Hui Liu
- Donald F. Sellitti
View Affiliations

Affiliations: Department of Medicine, Uniformed Services University of The Health Sciences, Bethesda, MD 20814‑4799, USA
Published online on: May 21, 2018 https://doi.org/10.3892/ol.2018.8751
Pages: 1285-1290

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous reports have indicated that the abundance of specific microRNAs (miRNA) contained within the exosome/microvesicle compartment of patient biofluids may be useful in diagnosing specific types of cancer. In the present study, the 786‑O cell line, which is derived from a clear cell renal cell carcinoma (ccRCC), was used as an in vitro ccRCC tumor model and the human renal proximal tubule cell line HK‑2 was used as its normal renal tissue control to investigate the similarities of exosomal content of selected ccRCC miRNA biomarkers in the supernatant with the content of those markers in the cells themselves. A PCR array identified miRNA biomarkers of solid RCC tumors (miR-210, MiR-34a, miR-155-5p and miR-150-5p) that were increased by 2-8 fold in 786-O exosomes compared with the control.. These were subsequently chosen for further investigation using TaqMan RT‑qPCR in addition to miR‑15a and miR‑205, which were selected based on prior interest as RCC biomarkers. MiR‑15a, ‑34a, ‑210 and ‑155 levels were significantly lower in exosomes when compared with that in whole cells but did not differ between the HK‑2 and 786‑O cells in either the cytoplasmic, exosome or exosome‑free supernatant fractions. By contrast, cytoplasmic miR‑150 and miR‑205 exhibited significant differences in concentration between the two cell lines. In addition, the cytoplasmic content of miR‑150 and miR‑205 was mirrored in the exosomal content of these miRNAs. Furthermore, the difference in exosomal miR‑205 content was statistically significant. The present study indicated that measurements of the exosomal content of miR‑205 and possibly miR‑150, but not those of the other examined miRNAs, are proportional to their respective contents in the cells that secreted them. These findings suggest that in vitro RCC systems may be useful in identifying miRNAs with sufficiently high levels of exportation into exosomes; and with sufficiently different expression levels between tumor and normal cells to serve as ccRCC biomarkers in vivo.

View Figures

View References

1	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Greef B and Eisen T: Medical treatment of renal cancer: New horizons. Br J Cancer. 115:505–516. 2016. View Article : Google Scholar : PubMed/NCBI
3	Stahlhut Espinosa CE and Slack FJ: The role of microRNAs in cancer. Yale J Biol Med. 79:131–140. 2006.PubMed/NCBI
4	Wuchty S, Arjona D, Bozdag S and Bauer PO: Involvement of microRNA families in cancer. Nuc Acids Res. 40:8219–8226. 2012. View Article : Google Scholar
5	Wang J, Zhang KY, Liu SM and Sen S: Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 19:1912–1938. 2014. View Article : Google Scholar : PubMed/NCBI
6	Sellitti DF and Doi SQ: MicroRNAs in renal cell carcinoma. Microrna. 4:26–35. 2015. View Article : Google Scholar : PubMed/NCBI
7	Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F and Takenaka A: Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 44:53–58. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
9	Wang C, Hu J, Lu M, Gu H, Zhou X, Chen X, Zen K, Zhang CY, Zhang T, et al: A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep. 5:76102015. View Article : Google Scholar : PubMed/NCBI
10	Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R and Slaby O: Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 10:552012. View Article : Google Scholar : PubMed/NCBI
11	Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, et al: Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Canc Epidemiol. 36:391–394. 2012. View Article : Google Scholar
12	von Brandenstein M, Pandarakalum JJ, Kroon L, Loeser H, Herden J, Braun G, Wendland K, Dienes HP, Engelmann U and Fries JW: MicroRNA 15a, inversely correlated to PKCα, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol. 180:1787–1797. 2012. View Article : Google Scholar : PubMed/NCBI
13	Butz H, Nofech-Mozes R, Ding Q, Khella HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M and Stewart R: et alExosomal microRNAs are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma. Eur Urol Focus. 2:210–218. 2016. View Article : Google Scholar : PubMed/NCBI
14	Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C and Czarnecka AM: Choosing the right cell line for renal cancer research. Mol Canc. 15:832016. View Article : Google Scholar
15	Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA and Torok-Storb B: HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 45:48–57. 1994. View Article : Google Scholar : PubMed/NCBI
16	Vlasov P, Doi SQ and Sellitti DF: FRTL-5 rat thyroid cells release thyroglobulin sequestered in exosomes: A possible novel mechanism for thyroglobulin processing in the thyroid. J Thyroid Res. 2016:92764022016. View Article : Google Scholar : PubMed/NCBI
17	Schwarzenbach H, da Silva AM, Calin G and Pantel K: Data normalization strategies for microRNA quantification. Clin Chem. 61:1333–1342. 2015. View Article : Google Scholar : PubMed/NCBI
18	Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C and Zhang L: Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol. 35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
19	Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS: Identification of a microRNA panel for clear-cell kidney cancer. Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
20	Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, et al: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 13:3918–3928. 2009. View Article : Google Scholar : PubMed/NCBI
21	Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, et al: Genome-wide microRNA expression profiling in renal cell carcinoma: Significant down-regulation of miR-141 and miR-200c. J Pathol. 216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
22	Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ and The BT: MicroRNA profiling of human kidney cancer subtypes. Int J Oncol. 35:109–114. 2009. View Article : Google Scholar : PubMed/NCBI
23	Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, et al: MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol. 222:41–51. 2010.PubMed/NCBI
24	Huang X, Liang M, Dittmar R and Wang L: Extracellular microRNAs in urologic malignancies: Chances and challenges. Int J Mol Sci. 14:14785–14799. 2013. View Article : Google Scholar : PubMed/NCBI
25	Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Canc Res. 75:1322–1331. 2015. View Article : Google Scholar
26	Chanudet E, Wozniak MB, Bouaoun L, Byrnes G, Mukeriya A, Zaridze D, Brennan P, Muller DC and Scelo G: Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease. Int J Cancer. 141:1730–1740. 2017. View Article : Google Scholar : PubMed/NCBI
27	Orang AV, Safaralizaden R and Hosseinpour Feizi MA: Insights into the diverse roles of miR-205 in human cancers. Asian Pac J Cancer Prev. 15:577–583. 2014. View Article : Google Scholar : PubMed/NCBI
28	Qin AY, Zhang XW, Liu L, Yu JP, Li H, Wang SZE, Ren XB and Cao S: Mir-205 in cancer: An angel or a devil? Eur J Cell Biol. 92:54–60. 2013. View Article : Google Scholar : PubMed/NCBI
29	Guduric-Fuchs J, O'Conner A, Camp B, O'Neill CL, Medina RJ and Simpson DA: Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics. 13:3572012. View Article : Google Scholar : PubMed/NCBI